FDA approves denosumab for SREs

FDA approved an sBLA from Amgen Inc. (NASDAQ:AMGN) for Xgeva denosumab to prevent skeletal-related events in patients with bone metastases from solid tumors. Denosumab is already approved in the U.S. ...